TABLE 2.
Clinical factors associated with Scedosporium species isolation, unadjusted and adjusteda (n = 19 023)
| Unadjusted | Adjusteda | |||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | P-value | Odds ratio | 95% CI | P-value | |
| Demographics | ||||||
| Baseline age, 10 year increments | 1.13 | 1.06, 1.20 | <0.001 | 1.16 | 1.07, 1.26 | <0.001 |
| Female | 1.26 | 1.07, 1.48 | 0.01 | 1.18 | 1.00, 1.39 | 0.05 |
| White vs non-white | 1.89 | 1.22, 2.94 | 0.004 | 1.69 | 1.09, 2.63 | 0.02 |
| F508del | 1.07 | 0.95, 1.21 | 0.27 | |||
| Disease characteristics | ||||||
| Pancreatic insufficiency | 1.36 | 1.03, 1.78 | 0.03 | 1.09 | 0.82, 1.47 | 0.54 |
| Baseline FEV1 % predicted, 10% increments | 0.92 | 0.89, 0.95 | <0.001 | 0.99 | 0.96, 1.04 | 0.88 |
| CFRD | 1.28 | 1.06, 1.54 | 0.01 | 0.91 | 0.75, 1.12 | 0.38 |
| Treatments | ||||||
| Inhaled antibiotics | 2.46 | 2.01, 3.00 | <0.001 | 2.01 | 1.61, 2.52 | <0.001 |
| Macrolide | 1.46 | 1.24, 1.73 | <0.001 | 1.00 | 0.83, 1.20 | 0.98 |
| IV antibiotic courses, number in baseline year | 1.18 | 1.13, 1.23 | <0.001 | 1.08 | 1.03, 1.14 | 0.04 |
| Inhaled corticosteroid | 1.12 | 0.95, 1.32 | 0.19 | 0.85 | 0.72, 1.00 | 0.06 |
| Infections | ||||||
| Pseudomonas aeruginosa | 1.57 | 1.32, 1.87 | <0.001 | 1.07 | 0.88, 1.29 | 0.51 |
| MRSA | 0.91 | 0.76, 1.09 | 0.29 | |||
| Burkholderia cepacia complex | 1.06 | 0.67, 1.66 | 0.81 | |||
FEV1, Forced expiratory volume in 1 second; CFRD, Cystic fibrosis related diabetes; IV, intravenous; MRSA, methicillin resistant Staphylococcus aureus. Bold effect estimates are the ones that are statistically significant.
a
Adjusted model includes baseline age, female, white race, pancreatic insufficiency, FEV1 percent predicted, CFRD, inhaled antibiotics, macrolide, IV antibiotic courses per year, Pseudomonas aeruginosa co-infection, and total number of encounters during study period.